3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Sell
21
PACB Quote, Financials, Valuation and Earnings
Last price:
$1.22
Seasonality move
:
-13.33%
Day range:
$1.18 - $1.30
52-week range:
$1.16 - $4.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.19x
P/B ratio:
0.70x
Volume:
10.8M
Avg. volume:
13.2M
1-year change:
-71.7%
Market cap:
$353.2M
Revenue:
$154M
EPS (TTM):
-$1.64
Analysts' Opinion
-
Consensus RatingPacific Biosciences of California has received a consensus rating of Hold. The company's average rating is a Hold based on 6 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.67, Pacific Biosciences of California has an estimated upside of 122.22% from its current price of $1.20.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $1.20.
Fair Value
-
According to the consensus of 14 analysts, Pacific Biosciences of California has 122.22% upside to fair value with a price target of $2.67 per share.
PACB vs. S&P 500
-
Over the past 5 trading days, Pacific Biosciences of California has underperformed the S&P 500 by -3.54% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pacific Biosciences of California does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pacific Biosciences of California revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Pacific Biosciences of California reported revenues of $39.2M.
Earnings Growth
-
Pacific Biosciences of California has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Pacific Biosciences of California reported earnings per share of -$0.49.
Enterprise value:
610.7M
EV / Invested capital:
0.53x
Price / LTM sales:
2.19x
EV / EBIT:
--
EV / Revenue:
3.97x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-2.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$37.3M
Return On Assets:
-20.21%
Net Income Margin (TTM):
-200.41%
Return On Equity:
-55.04%
Return On Invested Capital:
-21.98%
Operating Margin:
-162.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $128.3M | $200.5M | $154M | $58.4M | $39.2M | |
| Gross Profit | $49M | $52.8M | $37.3M | $9.6M | $10.1M | |
| Operating Income | -$304.8M | -$310.4M | -$290.7M | -$86.4M | -$63.7M | |
| EBITDA | -$282.5M | -$277.3M | -$247.9M | -$67.5M | $11.3M | |
| Diluted EPS | -$1.40 | -$1.21 | -$1.64 | -$0.31 | -$0.49 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $355.6M | $1.1B | $852.1M | $742M | $497.2M | |
| Total Assets | $414M | $2B | $1.8B | $1.7B | $1.3B | |
| Current Liabilities | $38.5M | $71.7M | $263.3M | $95M | $58.9M | |
| Total Liabilities | $78.5M | $1.2B | $1.2B | $1B | $753.9M | |
| Total Equity | $335.5M | $791M | $562.9M | $701.3M | $507.8M | |
| Total Debt | -- | $897.7M | $898.5M | $892.7M | $647.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$234.4M | -$262.2M | -$233M | -$65.2M | -$45.5M | |
| Cash From Investing | $101.4M | $151.6M | -$809K | $242.3M | $23.1M | |
| Cash From Financing | $10.1M | $191.3M | -$74.4M | -$781K | $812K | |
| Free Cash Flow | -$249M | -$274.1M | -$239.6M | -$66M | -$44.7M | |
PACB
Sector
Market Cap
$353.2M
$38.4M
Price % of 52-Week High
28.37%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
9.08%
-0.78%
1-Year Price Total Return
-71.7%
-39.05%
Beta (5-Year)
1.863
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.31
200-day SMA
Sell
Level
$1.75
Bollinger Bands (100)
Sell
Level
1.51 - 2.13
Chaikin Money Flow
Sell
Level
-305.3M
20-day SMA
Sell
Level
$1.47
Relative Strength Index (RSI14)
Sell
Level
36.21
ADX Line
Sell
Level
14.98
Williams %R
Buy
Level
-96
50-day SMA
Sell
Level
$1.63
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
283.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.0192)
Sell
CA Score
(Annual)
Level (-1.7596)
Sell
Beneish M-Score
(Annual)
Level (-1.526)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.9029)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Stock Forecast FAQ
In the current month, PACB has received 6 Buy ratings 8 Hold ratings, and 0 Sell ratings. The PACB average analyst price target in the past 3 months is $2.67.
-
Where Will Pacific Biosciences of California Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pacific Biosciences of California share price will rise to $2.67 per share over the next 12 months.
-
What Do Analysts Say About Pacific Biosciences of California?
Analysts are divided on their view about Pacific Biosciences of California share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pacific Biosciences of California is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Pacific Biosciences of California's Price Target?
The price target for Pacific Biosciences of California over the next 1-year time period is forecast to be $2.67 according to 14 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is PACB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pacific Biosciences of California is a Hold. 8 of 14 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of PACB?
You can purchase shares of Pacific Biosciences of California via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pacific Biosciences of California shares.
-
What Is The Pacific Biosciences of California Share Price Today?
Pacific Biosciences of California was last trading at $1.22 per share. This represents the most recent stock quote for Pacific Biosciences of California. Yesterday, Pacific Biosciences of California closed at $1.20 per share.
-
How To Buy Pacific Biosciences of California Stock Online?
In order to purchase Pacific Biosciences of California stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Tesla Stock: The Bear Case
The recent stock market drop has been a punishing time…
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Alerts
Sell
5
CABO alert for Mar 14
Cable One [CABO] is down 3.97% over the past day.
Sell
38
ADBE alert for Mar 14
Adobe [ADBE] is up 4.43% over the past day.
Sell
29
CAR alert for Mar 14
Avis Budget Group [CAR] is up 11.68% over the past day.
